Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895075 | 0.89 | TLR7 (0.48) | TLR7TLR8NUDT1KDM4EHDAC6 | |
| SCHEMBL4122028 | 0.89 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL4135322 | 0.88 | TLR7 (0.46) | TLR7TLR8NUDT1HDAC6 | |
| SCHEMBL4710315 | 0.87 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL18166863 | 0.87 | TLR7 (0.43) | TLR7TLR8NUDT1HDAC6 | |
| SCHEMBL4129145 | 0.86 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL4769814 | 0.85 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL1082723 | 0.85 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL2744880 | 0.83 | TLR7 (0.46) | TLR7TLR8NUDT1KDM4E | |
| SCHEMBL4142764 | 0.83 | TLR7 (0.60) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3085373-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1850850-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF IMMUNE RESPONSE MODIFIERS | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007100634-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2006091720-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142202-A1 | Compositions and methods for targeted delivery of immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885NUDT1 3151/4885 |
| US-20060142202-A1 | Compositions and methods for targeted delivery of immune response modifiers | CD47, IFNG, CLEC4M | TLR7 84/4885TLR8 57/4885NUDT1 4367/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885NUDT1 3151/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885NUDT1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.